In this video, InMed CEO Eric A. Adams speaks with BTV about InMed’s focus on cannabinoid-based pharmaceutical products. Mr. Adams talks about the company’s proprietary biosynthesis platform with potential to manufacture pharmaceutical-grade, high-yield cannabinoids.

Peer-reviewed Publication: Rare phytocannabinoids exert anti-inflammatory effects on human keratinocytes via the endocannabinoid system and MAPK signalling pathway
A peer-reviewed scientific study entitled “Rare phytocannabinoids exert anti-inflammatory effects on human keratinocytes via the endocannabinoid system and MAPK signalling pathway” has been published in the International